Budesonide ER (Uceris®)

Self administration - Oral

Indications for Prior Authorization 

Approvable for induction of remission in patients with active, mild to moderate ulcerative colitis

Patients must meet the following criteria for the indication(s) above.

Diagnosis of ulcerative colitis

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P&T Committee:

All non-FDA approved uses not listed in the approved indications

Recommended Dosing: 9 mg once daily

Maximum duration of therapy is 8 weeks

Approval: Eight weeks

Western Health Advantage Pharmacy and Therapeutics Committee

Approved/Revised: December 3 2013